Pure Global
NCT05718934

Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium

A Randomized Clinical Study to Compare Low Dose of Sugammadex to Standard Dose of Neostigmine and Glycopyrrolate for the Reversal of Rocuronium Induced Moderate Neuromuscular Block
Ciusss de L'Est de l'Île de Montréal·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Neuromuscular Blockade
Drug/Device/Intervention
Neostigmine and glycopyrrolate
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ciusss de L'Est de l'Île de Montréal
Location
Montreal, Canada
Timeline & enrollment
Phase
Phase 4
Start date
Nov 08, 2022
End date
Nov 01, 2023
Enrollment
144 participants
Primary outcome

Time for recovery from moderate NMB

Summary

The aim of this study is to compare the use of a low dose sugammadex and neostigmine combined
 to glycopyrrolate to reverse a rocuronium induced moderate neuromuscular blockade.

ICD-10 classifications
Skeletal muscle relaxants [neuromuscular blocking agents]Poisoning: Skeletal muscle relaxants [neuromuscular blocking agents]Other neuromuscular dysfunction of bladderNeuromuscular dysfunction of bladder, unspecifiedNeuromuscular scoliosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05718934
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05718934 through Pure Global AI's free database. This Phase 4 trial is sponsored by Ciusss de L'Est de l'Île de Montréal and is currently Recruiting. The study focuses on Neuromuscular Blockade. Target enrollment is 144 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.